Amarin Corporation (AMRN) PT Raised to $51 at H.C. Wainwright; REDUCE-IT Update is a 'Home run'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Amarin (AMRN) Mineral Oil Concerns Not an Oil Spill - Cantor Fitzgerald
November 13, 2018 7:45 AM ESTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $35 price target on Amarin Corporation (NASDAQ: AMRN) saying 'Let's Not Treat Mineral Oil Concerns Like An Oil Spill.'
Chen highlighted:
AMRN disclosed new data in its FAQs and in an 8-K which reinforces our view that mineral oil concerns in the placebo arm are overdone. Therefore, we continue to believe that... MoreAmarin Corp. (AMRN) Achieves Topline Primary & Secondary Endpoint Results from REDUCE-IT, Cardiovascular Outcomes Trial for Vascepa (icosapent ethyl)
November 12, 2018 6:11 AM ESTAmarin Corporation plc (NASDAQ: AMRN) announced today the primary results from the Vascepa® (icosapent ethyl) cardiovascular (CV) outcomes trial, REDUCE-IT, following presentation of the late-breaking clinical trial results at the 2018 Scientific Sessions of the American Heart Association (AHA) in Chicago, Illinois. REDUCE-IT primary results confirmed 25% relative risk reduction (RRR) for the topline primary endpoint result with... More
